ACINO COMPLETES ACQUISITION OF M8 PHARMACEUTICALS SIGNIFICANTLY EXPANDING PRESENCE AND CAPABILITIES IN LATIN AMERICA Zurich, Switzerland 4 December 2023: Acino, a Swiss pharmaceutical company...
UCB presents new data about the real-world experience of FINTEPLA
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
FINTEPLA®? (fenfluramine) oral solution has been recommended for marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) for treating seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients over two years old in the European Union (EU).
ATLANTA, Nov. 23, 2022 /PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the publication of long-term open-label extension (OLE) study results of FINTEPLA® (fenfluramine) CIV in Epilepsia. Long-term efficacy and safety findings showed that FINTEPLA, when added to a patient's current anti-epileptic treatment regimen for seizures associated with LGS, was effective in reducing the frequency of multiple seizure types and was generally well tolerated during a median treatment duration of 364 days.1 Study participants experienced a sustained reduction in the frequency of motor seizures including those that resulted in a drop or fall like generalized tonic-clonic seizures (GTCS), secondary GTCS, focal to bilateral tonic-clonic, tonic seizures, atonic seizures, and tonic-atonic seizures.1
Biopharmaceutical company UCB has announced that it has received a final appraisal determination from the National Institute for Healthcare Excellence (NICE), recommending Fintepla (fenfluramine). The treatment will be available as an add-on therapy for patients aged two year and above.
The global biopharma company UCB has announced the publication of results from its multi-centre, double-blind, placebo-controlled, parallel-group, randomised Phase III trial of fenfluramine in JAMA Neurology.
Healthcare infrastructure company Capable Health announced today it has raised $6 million in seed funding led by M13, with participation from...
UCB has won FDA approval for Fintepla as a treatment seizures associated with rare childhood epilepsy Lennox-Gastaut Syndrome (LGS), raising the pressure on Jazz Pharma’s rival therapy Epidiolex.
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patientsLGS is a debilitating childhood-onset...